Evidence‑Based Management of RSV and Rhinovirus in Infants

Supportive Care Recommendations

Provide adequate hydration and nutrition by continuing oral feeds in well‑appearing infants (no feeding difficulty) – American Academy of Pediatrics (AAP) recommendation. 1
Supplemental oxygen is not required when infants maintain saturations ≥ 90% and show no signs of respiratory distress – AAP guideline. 1

Routine bronchodilator therapy (e.g., albuterol) offers no benefit in RSV bronchiolitis and should be withheld – AAP guideline. 1
Systemic corticosteroids have not demonstrated efficacy and are not recommended – AAP guideline. 1
Antibiotics are unnecessary for viral RSV/rhinovirus infections unless a secondary bacterial infection is documented – AAP guideline. 1
Hypertonic saline nebulization is not advised for routine management of these viral infections – AAP guideline. 1
Routine diagnostic testing (chest radiography, laboratory panels) is not indicated in well‑appearing infants – AAP guideline. 1

Hospitalization should be considered if oxygen saturation persistently falls below 90% despite supportive care – AAP guideline. 1

Strict hand‑hygiene practices are the most effective measure to reduce transmission of RSV and rhinovirus – AAP infection‑control recommendation. [2][3]4
Limit infant exposure to crowded settings, tobacco smoke, and group childcare during RSV season to lower infection risk – AAP recommendation. [2][3]4
Breastfeeding is encouraged, although its specific protective effect against RSV remains uncertain – AAP recommendation. [2][3]
Palivizumab prophylaxis is reserved for infants with high‑risk conditions (e.g., chronic lung disease, significant congenital heart disease, severe airway anomalies); otherwise, it is not indicated – AAP immunoprophylaxis guideline. [5][6][7][8]
Newer monoclonal antibodies (nirsevimab or clesrovimab) are now recommended for all infants entering their first RSV season, offering broader protection – AAP update (2025). 9
Maternal RSV vaccination administered at 32–36 weeks gestation provides protection comparable to monoclonal antibodies for newborns – AAP recommendation (2025). 9

Do not prescribe unnecessary medications simply to meet parental expectations; focus on education about the viral, self‑limited nature of the illness – AAP guideline. 1
Continuous pulse‑oximetry monitoring in well‑appearing infants can lead to overtreatment of transient desaturations and should be avoided – AAP guideline. 1
Routine viral testing (RSV, rhinovirus) is not required unless the result will alter patient management (e.g., cohorting in a hospital setting) – AAP guideline. 1